中重度系统性红斑狼疮的实用性治疗目标及其对临床诊疗与试验设计的意义:持续DORIS或LLDAS至少6个月即足够,而持续至少24个月可确保对无损害进展的高特异性
该历史队列纳入348例活动性中重度SLE患者、中位随访5年,评估持续DORIS与LLDAS的可行性及其对损害、复发和不良结局的影响。持续DORIS或LLDAS≥6个月分别见于41.1%和80.4%的患者,均与损害累积和严重复发风险降低相关。以关节炎和皮肤黏膜病变为主的患者DORIS/LLDAS达标率较低。
要点
- 中重度SLE中持续DORIS≥6个月占41.1%、持续LLDAS≥6个月占80.4%,均与损害累积和严重复发风险降低相关。
- DORIS≥50%时间或≥24个月、LLDAS≥60%时间或≥36个月在可行性与无损害特异性间达最佳平衡。
- 以关节炎和皮肤黏膜病变为主的患者DORIS/LLDAS达标率低于主要器官受累者,代表未满足的治疗需求。
核心结论
- 在中重度SLE中,持续DORIS或LLDAS至少6个月即足够,而持续至少24个月可确保对无损害进展更高的特异性,从而促进达标治疗策略和临床试验。
- 关节炎和皮肤病变代表未满足的治疗需求,可能从新型生物制剂中获益。
研究设计与样本
- 历史队列研究纳入348例活动性中重度SLE患者,中位随访5年。
- 活动性SLE定义为医生整体评估≥1.5和/或SLE疾病活动指数2000≥6且需要强化治疗。
- 监测DORIS/LLDAS、器官损害、复发和不良事件,采用共享脆弱生存模型、广义线性模型和K均值聚类分析。
主要发现
- 持续DORIS≥6个月见于41.1%的患者,持续LLDAS≥6个月见于80.4%的患者。
- 持续DORIS≥6个月与损害累积风险降低相关(HR 0.58,95%CI 0.36至0.93),持续LLDAS≥6个月与损害累积风险降低相关(HR 0.61,95%CI 0.43至0.86)。
- 持续DORIS≥6个月与严重复发风险降低相关(HR 0.14,95%CI 0.08至0.27),持续LLDAS≥6个月与严重复发风险降低相关(HR 0.19,95%CI 0.13至0.27)。
- 无DORIS的LLDAS也具有保护作用:损害HR 0.65(95%CI 0.43至0.98),复发HR 0.49(95%CI 0.36至0.67)。
- 这些目标与严重不良事件风险比降低(RR 0.56至0.71)、住院(RR 0.70)和死亡(RR 0.06至0.13)相关。
关键数值与推荐
- DORIS≥50%时间或≥24个月、LLDAS≥60%时间或≥36个月,在可行性(20.2%至41.7%)与无损害结局特异性(73.3%至86.1%)之间达到最佳平衡。
- 以关节炎和皮肤黏膜病变为主的患者DORIS/LLDAS达标率低于主要器官受累者;前者更常用传统药物,后者更常用强效免疫抑制/生物制剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Treatment targets in systemic lupus erythematosus (SLE) have been validated in unselected-in terms of severity-cohorts, which limits their generalisability. We assessed remission (Definition of Remission in SLE (DORIS)) and Lupus Low Disease Activity State (LLDAS) in a historical cohort of 348 patients with active moderate-to-severe disease and median follow-up of 5 years. METHODS: Active SLE was defined as Physician Global Assessment ≥1.5 and/or SLE Disease Activity Index 2000 ≥6, requiring therapy intensification. DORIS/LLDAS, organ damage, flares and adverse events were monitored. Shared frailty survival, generalised linear models and K-means clustering were applied. RESULTS: Sustained DORIS and LLDAS for ≥6 months occurred in 41.1% and 80.4%, respectively, and resulted in reduced damage accrual (HR: 0.58; 95% CI 0.36 to 0.93 and 0.61; 0.43 to 0.86) and severe flares (HR: 0.14; 0.08 to 0.27 and 0.19; 0.13 to 0.27). LLDAS without DORIS was also protective (HR: 0.65; 0.43 to 0.98 for damage, 0.49; 0.36 to 0.67 for flares). Models fitting increasing duration of targets showed that DORIS ≥50% and LLDAS ≥60% of time, or alternatively, ≥24 and ≥36 months, achieved optimal balance between feasibility (20.2-41.7%) and specificity (73.3-86.1%) for damage-free outcome. These targets were linked to reduced serious adverse events (risk ratio (RR): 0.56-0.71), hospitalisation (RR: 0.70) and mortality (RR: 0.06-0.13). Patients with predominant arthritis and mucocutaneous disease experienced reduced DORIS/LLDAS, compared with counterparts with major organ involvement. Conventional drugs were more frequently used in the former group, whereas potent immunosuppressive/biological agents in the latter. CONCLUSIONS: In moderate-to-severe SLE, sustained DORIS/LLDAS for at least 6 months is sufficient, while attainment for at least 24 months ensures higher specificity for damage-free progression, thus facilitating treat-to-target strategies and clinical trials. Arthritis and skin disease represent unmet therapeutic needs that could benefit from novel biologics.
引用
- Pitsigavdaki S, Nikoloudaki M, Garantziotis P, et al. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Ann Rheum Dis. 2024. PMID: 38233103. doi:10.1136/ard-2023-224919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。